Posted by Michael Wonder on 14 Jun 2023
Dabrafenib mesylate and trametinib dimethyl sulphoxide for the treatment of patients with advanced BRAF V600 mutation positive non-small-cell lung cancer
14 June 2023 - NICE has published final evidence-based recommendations on the use of dabrafenib mesylate (Tafinlar) and trametinib dimethyl sulphoxide (Mekinist) for the treatment of adults with advanced BRAF V600 mutation positive non-small-cell lung cancer.
The combination of dabrafenib mesylate and trametinib dimethyl sulphoxide is recommended as an option for the first-line treatment of adults with advanced BRAF V600 mutation positive non-small-cell lung cancer only if Novartis provides the two medicines according to the commercial arrangement.
